The Australia & New
Zealand research antibodies market size is expected to reach
USD 186.6 million by 2026 according to a new report by Grand View Research,
Inc., exhibiting a CAGR of 8.4%. Drivers of this market include rise in R&D
initiatives being undertaken by biopharmaceutical & biotechnology
companies, increase in government investments on R&D, and growth in
neurobiology & stem cell research.
Rise
in R&D investments and research activities by various pharmaceutical and
biotechnology companies to develop new & innovative products is anticipated
to fuel market growth. For instance, in March 2019, the Federal Government
invested USD 150 million in Stem Cells Australia and University of Melbourne to
support R&D pertaining to stem cell and explore new ways to treat various
life-threatening conditions such as stroke, congenital heart disease, and
kidney disease.
Growth
in stem cell and neurobiology-based research is expected to boost the market
during the forecast period. There are a number of neurobiology-based research
institutes in Australia. For instance, the Center of Research Excellence in
Neuromuscular Disorders, Australia, is a collaboration between neuromuscular
experts.
Ongoing
launch of new products is anticipated to fuel market growth over the forecast
period. For instance, in April 2019, Bio-Rad launched a range of
isotype-specific secondary antibodies-IgG1, IgG2a, and IgG2b. These products
are used for specificity in ELISA, imaging, western blotting, and flow
cytometry as well as to improve signaling.
Increasing
adoption of strategies, such as collaborations and acquisitions, by leading
market players is expected to fuel market growth. For instance, in March 2016,
Thermo Fisher Scientific Inc., announced the acquisition of Affymetrix, Inc.
This strategic acquisition was aimed at strengthening the company’s position in
the field of bioscience and expanding its portfolio of antibodies.
New
Zealand has been investing heavily in R&D in order to promote trade in
biotechnology sector. According to Research, Science and Innovation System
Performance Report, the nation’s total expenditure on R&D was estimated to
be 1.23% of GDP in 2016. This was funded by both public and private firms in
New Zealand. Data from the same source also indicates that the country’s
science system is highly productive in terms of publications per researcher,
with over USD 653,400 spent on research and higher education.
Browse
Details of Report @
https://www.grandviewresearch.com/industry-analysis/australia-new-zealand-research-antibodies-market
https://www.grandviewresearch.com/industry-analysis/australia-new-zealand-research-antibodies-market
Further key findings from the report suggest:
- Primary
antibodies held dominant share of the product segment in 2018. This can be
attributed to wide applications of these antibodies in research
- Monoclonal
antibodies held significant share of the type segment in 2018, mainly due
to their efficient staining properties and high specificity for detection
of antigens
- Western
blotting held the largest share of the technology segment owing to rising
demand for rapid diagnostic methods
- On the basis
of technology, ELISA is anticipated to witness the highest CAGR during the
forecast period, owing to conventional use of polyclonal antibodies for
sandwich ELISA
- On the basis
of source, mouse segment held the largest share of the Australia & New
Zealand research antibodies market in 2018, as mice are convenient to use
during production of antibodies for research purposes.
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment